Skip to main content

Blood Sugar

A six-week study of Tandem’s first automated insulin delivery device with Dexcom’s G5 CGM
First trial next month, launch expected in 2-3 years; Dexcom CGM included; a big commitment to diabetes tech innovation from an insulin company
A workshop hosted by the JDRF and Helmsley Charitable Trust brought together leaders in the field to discuss opportunities and advances in the treatment and possible...
The diaTribe Foundation and TCOYD host discussion at ADA focusing on access, outcomes beyond A1c, and future expectations
A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide
How it works and why it could help with exercise challenges. Plus, how diaTribe readers can try it for free
What does donated diabetes data tell us about time-in-range across different age groups?
Comparing Medtronic’s MiniMed 670G to injections and pumps in people with type 1 diabetes, with and without CGM; enrollment to open in May at some trial locations
A currently-enrolling trial is investigating a new arthritis medication along with type 2 diabetes drug Victoza, aiming to preserve insulin production in people with...
Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA
The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins
Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba
Bigfoot Biomedical and Abbott partner to use “next-generation” FreeStyle Libre glucose monitoring sensor (no fingersticks needed) with Bigfoot’s automated insulin...
How do I stay in range while sleeping?
Novo Nordisk’s newest insulin receives EMA approval; expected to launch in the first half of 2017
Instead of “avoid long-term complications,” Adam Brown focuses on something more motivating and uplifting
Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits
Amalgam Rx receives FDA clearance for basal insulin dosing app, iSage Rx; available with a prescription to adjust Lantus, Levemir, Toujeo, Tresiba, and Basaglar
Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA
Faster version of Novo Nordisk’s NovoLog approved in the US for type 1 and type 2 diabetes, launch expected as early as end of 2017

Pages